Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyDyclonine
Targets (1)
Identification
- Name
- Dyclonine
- Accession Number
- DB00645 (APRD00940)
- Type
- Small Molecule
- Groups
- Approved
- Description
Dyclonine is an oral anaesthetic found in Sucrets, an over the counter throat lozenge. It is also found in some varieties of the Cepacol sore throat spray.
- Structure
Structure for DB00645 (Dyclonine)
- Synonyms
- 1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone
- 2-(1-Piperidyl)ethyl P-butoxyphenyl ketone
- 3-Piperidino-4'-butoxypropiophenone
- 4-Butoxy-beta-piperidinopropiophenone
- 4-N-Butoxy-beta-(1-piperidyl)propiophenone
- 4'-Butoxy-3-piperidinopropiophenone
- Diclonina
- Dyclocaine
- Dyclonin
- Dyclonine
- Dycloninum
- External IDs
- Not Available
- Product Ingredients
Ingredient UNII CAS InChI Key Dyclonine hydrochloride ZEC193879Q 536-43-6 KNZADIMHVBBPOA-UHFFFAOYSA-N - Approved Prescription Products
- Not Available
- Approved Generic Prescription Products
- Not Available
- Approved Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Cepacol Sore Throat Spray Spray 0.1 % Oral Reckitt Benckiser 1999-07-01 2012-03-23 Canada 
PerioRinse Rinse .1 g/100mL Dental; Oral; Topical; Transmucosal Centura Pharmaceuticals, Inc 2016-06-16 Not applicable US 
Sore Throat Relief Lozenge 3 mg Oral Stanley Pharmaceuticals, A Division Of Vita Health Products Inc. Not applicable Not applicable Canada Sucrets Black Cherry Lozenge 3 mg/1 Oral Insight Pharmaceuticals 2009-06-18 Not applicable US Sucrets Childrens Cherry Lozenge 1.2 mg/1 Oral Insight Pharmaceuticals 2009-07-28 Not applicable US Sucrets Extra Strength Mint Flav.loz 3mg Lozenge 3 mg Oral Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc. 1994-12-31 1998-08-25 Canada Sucrets for Kids Lozenge 1.2 mg Oral Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc. 1992-12-31 1998-08-25 Canada Sucrets for Kids Lozenge 1.2 mg Oral Insight Pharmaceuticals 1997-08-15 Not applicable Canada Sucrets MS Wintergreen Lozenge 3 mg/1 Oral Insight Pharmaceuticals 2009-07-28 Not applicable US Sucrets Regular Strength Lemon Flav.loz 2mg Lozenge 2 mg Oral Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc. 1994-12-31 1998-08-25 Canada Sucrets Regular Strength Lemon Flavoured Lozenges Lozenge 2 mg Oral Heritage Brands, A Subsidiary Of Insight Pharmaceuticals Llc 1997-08-15 2009-06-19 Canada Sucrets Sore Throat Lozenge 3 mg Oral Insight Pharmaceuticals 2007-05-31 Not applicable Canada Sucrets Sore Throat Spray 0.1% Cherry Aerosol .1 % Oral Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc. 1993-12-31 1996-09-12 Canada Sucrets Wild Cherry Lozenge 2 mg/1 Oral Insight Pharmaceuticals 2009-07-28 Not applicable US - Unapproved/Other Products
- Not Available
- International/Other Brands
- Dyclone (AstraZeneca) / Sucrets (Insight Pharmaceuticals)
- Brand mixtures
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Ambix First Aid Cream Topical Organics Corporation Of America Dba Ambix Laboratories 2013-08-22 Not applicable US Benzethonium chloride and Dyclonine hydrochloride Liquid Topical Walgreen 2012-01-12 Not applicable US Benzethonium chloride Plus Dyclonine hydrochloride Liquid Topical Cvs Health 2014-07-10 Not applicable US Cepacol Sore Throat Liquid Oral Reckitt Benckiser 2011-05-20 Not applicable US Skin Shield Liquid Topical Insight Pharmaceuticals 2010-06-01 Not applicable US Skin Shield Liquid Bandage Liquid Topical Del Pharmaceuticals Inc. 1983-12-31 1998-02-16 Canada Sucrets Complete Lozenge Oral Insight Pharmaceuticals 2007-05-31 Not applicable Canada Sucrets Complete Cool Citrus Lozenge Oral Insight Pharmaceuticals 2009-07-28 Not applicable US Sucrets Complete Sore Throat, Cough and Irritation Lozenge Oral Insight Pharmaceuticals Not applicable Not applicable Canada Sucrets Complete Vapor Cherry Lozenge Oral Insight Pharmaceuticals 2009-07-31 Not applicable US Tanac Medicated Gel Gel Topical Del Pharmaceuticals Inc. 1994-12-31 2006-07-12 Canada - Categories
- UNII
- 078A24Q30O
- CAS number
- 586-60-7
- Weight
- Average: 289.4125
Monoisotopic: 289.204179113 - Chemical Formula
- C18H27NO2
- InChI Key
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3
- IUPAC Name
- 1-(4-butoxyphenyl)-3-(piperidin-1-yl)propan-1-one
- SMILES
- CCCCOC1=CC=C(C=C1)C(=O)CCN1CCCCC1
Pharmacology
- Indication
Used to provide topical anesthesia of accessible mucous membranes prior to examination, endoscopy or instrumentation, or other procedures involving the esophagus, larynx, mouth, pharynx or throat, respiratory tract or trachea, urinary tract, or vagina. Also used to suppress the gag reflex and/or other laryngeal and esophageal reflexes to facilitate dental examination or procedures (including oral surgery), endoscopy, or intubation. Also used for relief of canker sores, cold sores or fever blister.
- Structured Indications
- Pharmacodynamics
Dyclonine is an oral anasthetic. If substantial quantities of local anesthetics are absorbed through the mucosa, actions on the central nervous system (CNS) may cause CNS stimulation and/or CNS depression. Actions on the cardiovascular system may cause depression of cardiac conduction and excitability and, with some of these agents, peripheral vasodilation.
- Mechanism of action
Local anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade.
Target Actions Organism ASodium channel protein type 10 subunit alpha inhibitorHuman - Absorption
Readily absorbed through mucous membranes into the systemic circulation. The rate of absorption is influenced by the vascularity or rate of blood flow at the site of application, the total dosage (concentration and volume) administered, and the duration of exposure. Absorption from mucous membranes of the throat or respiratory tract may be especially rapid.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
Approximately 30 to 60 minutes.
- Clearance
- Not Available
- Toxicity
Symptoms of overdose include cardiovascular system depression, CNS toxicity, and methemoglobinemia.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7-Nitroindazole The risk or severity of adverse effects can be increased when Dyclonine is combined with 7-Nitroindazole. Experimental Acepromazine The risk or severity of adverse effects can be increased when Dyclonine is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Dyclonine is combined with Aceprometazine. Approved Adipiplon The risk or severity of adverse effects can be increased when Dyclonine is combined with adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Dyclonine is combined with Agomelatine. Approved, Investigational Alfaxalone The risk or severity of adverse effects can be increased when Dyclonine is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Dyclonine is combined with Alfentanil. Approved, Illicit Allopregnanolone The risk or severity of adverse effects can be increased when Dyclonine is combined with Sage 547. Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Dyclonine is combined with Alphacetylmethadol. Experimental, Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Dyclonine. Approved, Illicit, Investigational Amisulpride The risk or severity of adverse effects can be increased when Dyclonine is combined with Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Dyclonine is combined with Amitriptyline. Approved Amobarbital The risk or severity of adverse effects can be increased when Dyclonine is combined with Amobarbital. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Dyclonine is combined with Amoxapine. Approved Amperozide The risk or severity of adverse effects can be increased when Dyclonine is combined with Amperozide. Experimental Aripiprazole The risk or severity of adverse effects can be increased when Dyclonine is combined with Aripiprazole. Approved, Investigational Articaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Dyclonine is combined with Asenapine. Approved Azaperone The risk or severity of adverse effects can be increased when Dyclonine is combined with Azaperone. Vet Approved Azelastine Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Azelastine The risk or severity of adverse effects can be increased when Dyclonine is combined with Azelastine. Approved Baclofen The risk or severity of adverse effects can be increased when Dyclonine is combined with Baclofen. Approved Barbital The risk or severity of adverse effects can be increased when Dyclonine is combined with Barbital. Illicit Benperidol The risk or severity of adverse effects can be increased when Dyclonine is combined with Benperidol. Investigational Benzocaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Benzocaine. Approved Benzyl alcohol The risk or severity of adverse effects can be increased when Dyclonine is combined with Benzyl alcohol. Approved Brexpiprazole The risk or severity of adverse effects can be increased when Dyclonine is combined with Brexpiprazole. Approved Brimonidine The risk or severity of adverse effects can be increased when Dyclonine is combined with Brimonidine. Approved Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved Bromazepam The risk or severity of adverse effects can be increased when Dyclonine is combined with Bromazepam. Approved, Illicit Brompheniramine The risk or severity of adverse effects can be increased when Dyclonine is combined with Brompheniramine. Approved Brotizolam The risk or severity of adverse effects can be increased when Dyclonine is combined with Brotizolam. Approved, Withdrawn Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dyclonine. Approved, Investigational Buprenorphine Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Dyclonine. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Dyclonine. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Dyclonine is combined with Butalbital. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Dyclonine is combined with Butamben. Approved Butethal The risk or severity of adverse effects can be increased when Dyclonine is combined with Butethal. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Dyclonine. Approved, Illicit, Vet Approved Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Dyclonine. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Dyclonine is combined with Carbinoxamine. Approved Carfentanil The risk or severity of adverse effects can be increased when Dyclonine is combined with Carfentanil. Illicit, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Dyclonine is combined with Carisoprodol. Approved Cetirizine The risk or severity of adverse effects can be increased when Dyclonine is combined with Cetirizine. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Dyclonine is combined with Chloral hydrate. Approved, Illicit, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dyclonine. Approved, Illicit Chlormezanone The risk or severity of adverse effects can be increased when Dyclonine is combined with Chlormezanone. Approved, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Chloroprocaine. Approved Chlorphenamine The risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorphenamine. Approved Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dyclonine. Approved, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorprothixene. Approved, Withdrawn Chlorzoxazone The risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorzoxazone. Approved Cinchocaine The risk or severity of adverse effects can be increased when Cinchocaine is combined with Dyclonine. Approved, Vet Approved Citalopram The risk or severity of adverse effects can be increased when Dyclonine is combined with Citalopram. Approved Clemastine The risk or severity of adverse effects can be increased when Dyclonine is combined with Clemastine. Approved Clidinium The risk or severity of adverse effects can be increased when Dyclonine is combined with Clidinium. Approved Clobazam The risk or severity of adverse effects can be increased when Dyclonine is combined with Clobazam. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Dyclonine is combined with clomethiazole. Investigational Clomipramine The risk or severity of adverse effects can be increased when Dyclonine is combined with Clomipramine. Approved, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Dyclonine is combined with Clonazepam. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Dyclonine is combined with Clonidine. Approved Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Dyclonine. Approved, Illicit Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Dyclonine. Approved Cocaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Cocaine. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Dyclonine. Approved, Illicit Cyclizine The risk or severity of adverse effects can be increased when Dyclonine is combined with Cyclizine. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Dyclonine is combined with Cyclobenzaprine. Approved Cyproheptadine The risk or severity of adverse effects can be increased when Dyclonine is combined with Cyproheptadine. Approved Dantrolene The risk or severity of adverse effects can be increased when Dyclonine is combined with Dantrolene. Approved Dapiprazole The risk or severity of adverse effects can be increased when Dapiprazole is combined with Dyclonine. Approved Dapoxetine The risk or severity of adverse effects can be increased when Dyclonine is combined with Dapoxetine. Investigational Deramciclane The risk or severity of adverse effects can be increased when Dyclonine is combined with deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Dyclonine is combined with Desflurane. Approved Desipramine The risk or severity of adverse effects can be increased when Dyclonine is combined with Desipramine. Approved Desloratadine The risk or severity of adverse effects can be increased when Dyclonine is combined with Desloratadine. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Dyclonine is combined with Desvenlafaxine. Approved Detomidine The risk or severity of adverse effects can be increased when Dyclonine is combined with Detomidine. Vet Approved Dexbrompheniramine The risk or severity of adverse effects can be increased when Dyclonine is combined with Dexbrompheniramine. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dyclonine. Approved, Vet Approved Dextromoramide The risk or severity of adverse effects can be increased when Dyclonine is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Dyclonine is combined with Dextropropoxyphene. Approved, Illicit, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Dyclonine is combined with Dezocine. Approved Diazepam The risk or severity of adverse effects can be increased when Dyclonine is combined with Diazepam. Approved, Illicit, Vet Approved Difenoxin The risk or severity of adverse effects can be increased when Dyclonine is combined with Difenoxin. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydrocodeine. Approved, Illicit Dihydroetorphine The risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Dyclonine is combined with Dihydromorphine. Experimental, Illicit Dimenhydrinate The risk or severity of adverse effects can be increased when Dyclonine is combined with Dimenhydrinate. Approved Diphenhydramine The risk or severity of adverse effects can be increased when Dyclonine is combined with Diphenhydramine. Approved Diphenoxylate The risk or severity of adverse effects can be increased when Dyclonine is combined with Diphenoxylate. Approved, Illicit Doramectin The risk or severity of adverse effects can be increased when Dyclonine is combined with Doramectin. Vet Approved Doxepin The risk or severity of adverse effects can be increased when Dyclonine is combined with Doxepin. Approved Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Dyclonine is combined with DPDPE. Investigational Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved, Illicit Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Dyclonine is combined with Drotebanol. Experimental, Illicit Duloxetine The risk or severity of adverse effects can be increased when Dyclonine is combined with Duloxetine. Approved Ecgonine The risk or severity of adverse effects can be increased when Dyclonine is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Dyclonine is combined with Ecopipam. Investigational Efavirenz The risk or severity of adverse effects can be increased when Dyclonine is combined with Efavirenz. Approved, Investigational Eltanolone The risk or severity of adverse effects can be increased when Dyclonine is combined with Pregnanolone. Investigational Enflurane The risk or severity of adverse effects can be increased when Enflurane is combined with Dyclonine. Approved, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Dyclonine is combined with Entacapone. Approved, Investigational Escitalopram The risk or severity of adverse effects can be increased when Dyclonine is combined with Escitalopram. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Dyclonine is combined with Estazolam. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Dyclonine. Approved Ethanol Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dyclonine. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Dyclonine is combined with Ethosuximide. Approved Ethotoin The risk or severity of adverse effects can be increased when Dyclonine is combined with Ethotoin. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl carbamate. Withdrawn Ethyl loflazepate The risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Dyclonine is combined with Ethylmorphine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Dyclonine is combined with Etifoxine. Withdrawn Etizolam The risk or severity of adverse effects can be increased when Dyclonine is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Etomidate is combined with Dyclonine. Approved Etoperidone The risk or severity of adverse effects can be increased when Dyclonine is combined with Etoperidone. Approved Etorphine The risk or severity of adverse effects can be increased when Dyclonine is combined with Etorphine. Illicit, Vet Approved Ezogabine The risk or severity of adverse effects can be increased when Dyclonine is combined with Ezogabine. Approved Felbamate The risk or severity of adverse effects can be increased when Dyclonine is combined with Felbamate. Approved Fencamfamine The risk or severity of adverse effects can be increased when Dyclonine is combined with Fencamfamine. Approved, Illicit, Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Dyclonine is combined with Fentanyl. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Dyclonine is combined with Fexofenadine. Approved Flibanserin The risk or severity of adverse effects can be increased when Dyclonine is combined with Flibanserin. Approved Fludiazepam The risk or severity of adverse effects can be increased when Dyclonine is combined with Fludiazepam. Approved, Illicit Flunarizine The risk or severity of adverse effects can be increased when Dyclonine is combined with Flunarizine. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Dyclonine is combined with Flunitrazepam. Approved, Illicit Fluoxetine The risk or severity of adverse effects can be increased when Dyclonine is combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Dyclonine is combined with Flupentixol. Approved, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Dyclonine. Approved Flurazepam The risk or severity of adverse effects can be increased when Dyclonine is combined with Flurazepam. Approved, Illicit Fluspirilene The risk or severity of adverse effects can be increased when Dyclonine is combined with Fluspirilene. Approved Fluticasone propionate The risk or severity of adverse effects can be increased when Dyclonine is combined with Fluticasone Propionate. Approved Fluvoxamine The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dyclonine. Approved, Investigational Fosphenytoin The risk or severity of adverse effects can be increased when Dyclonine is combined with Fosphenytoin. Approved Fospropofol The risk or severity of adverse effects can be increased when Dyclonine is combined with Fospropofol. Approved, Illicit Gabapentin The risk or severity of adverse effects can be increased when Dyclonine is combined with Gabapentin. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Dyclonine is combined with gabapentin enacarbil. Approved Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Dyclonine is combined with Gamma Hydroxybutyric Acid. Approved, Illicit Gepirone The risk or severity of adverse effects can be increased when Dyclonine is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Dyclonine is combined with Glutethimide. Approved, Illicit Guanfacine The risk or severity of adverse effects can be increased when Dyclonine is combined with Guanfacine. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Dyclonine is combined with Halazepam. Approved, Illicit, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Haloperidol is combined with Dyclonine. Approved Halothane The risk or severity of adverse effects can be increased when Dyclonine is combined with Halothane. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Dyclonine is combined with Heroin. Approved, Illicit Hexobarbital The risk or severity of adverse effects can be increased when Dyclonine is combined with Hexobarbital. Approved Hyaluronidase The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dyclonine. Approved, Investigational Hydrocodone Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dyclonine. Approved, Illicit Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved Iloperidone The risk or severity of adverse effects can be increased when Dyclonine is combined with Iloperidone. Approved Imipramine The risk or severity of adverse effects can be increased when Dyclonine is combined with Imipramine. Approved Indalpine The risk or severity of adverse effects can be increased when Dyclonine is combined with Indalpine. Investigational, Withdrawn Isoflurane The risk or severity of adverse effects can be increased when Dyclonine is combined with Isoflurane. Approved, Vet Approved Ketamine The risk or severity of adverse effects can be increased when Dyclonine is combined with Ketamine. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Dyclonine is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Dyclonine is combined with Ketobemidone. Approved Lamotrigine The risk or severity of adverse effects can be increased when Dyclonine is combined with Lamotrigine. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Dyclonine is combined with Levetiracetam. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Levobupivacaine. Approved Levocabastine The risk or severity of adverse effects can be increased when Dyclonine is combined with Levocabastine. Approved Levocetirizine The risk or severity of adverse effects can be increased when Dyclonine is combined with Levocetirizine. Approved Levodopa The risk or severity of adverse effects can be increased when Dyclonine is combined with Levodopa. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Dyclonine is combined with Levomethadyl Acetate. Approved Levomilnacipran The risk or severity of adverse effects can be increased when Dyclonine is combined with Levomilnacipran. Approved Levorphanol The risk or severity of adverse effects can be increased when Dyclonine is combined with Levorphanol. Approved Lidocaine The risk or severity of adverse effects can be increased when Lidocaine is combined with Dyclonine. Approved, Vet Approved Lithium The risk or severity of adverse effects can be increased when Dyclonine is combined with Lithium. Approved Lofentanil The risk or severity of adverse effects can be increased when Dyclonine is combined with Lofentanil. Illicit Loratadine The risk or severity of adverse effects can be increased when Dyclonine is combined with Loratadine. Approved Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Dyclonine. Approved Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Dyclonine. Approved Lurasidone The risk or severity of adverse effects can be increased when Dyclonine is combined with Lurasidone. Approved Magnesium Sulfate Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved, Vet Approved Maprotiline The risk or severity of adverse effects can be increased when Dyclonine is combined with Maprotiline. Approved Meclizine The risk or severity of adverse effects can be increased when Dyclonine is combined with Meclizine. Approved Medetomidine The risk or severity of adverse effects can be increased when Dyclonine is combined with Medetomidine. Vet Approved Melatonin The risk or severity of adverse effects can be increased when Dyclonine is combined with Melatonin. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Dyclonine is combined with Melperone. Approved Mepivacaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Mepivacaine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Dyclonine. Approved, Illicit Mesoridazine The risk or severity of adverse effects can be increased when Dyclonine is combined with Mesoridazine. Approved Metaxalone The risk or severity of adverse effects can be increased when Dyclonine is combined with Metaxalone. Approved Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Dyclonine. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Dyclonine is combined with Methadyl Acetate. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Dyclonine is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Dyclonine is combined with Methaqualone. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Dyclonine is combined with Methocarbamol. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Dyclonine. Approved Methotrimeprazine Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved Methoxyflurane The risk or severity of adverse effects can be increased when Dyclonine is combined with Methoxyflurane. Approved, Vet Approved Methsuximide The risk or severity of adverse effects can be increased when Dyclonine is combined with Methsuximide. Approved Methylecgonine The risk or severity of adverse effects can be increased when Dyclonine is combined with ECGONINE METHYL ESTER. Experimental Methylphenobarbital The risk or severity of adverse effects can be increased when Dyclonine is combined with Methylphenobarbital. Approved Metyrosine Dyclonine may increase the sedative activities of Metyrosine. Approved Midazolam The risk or severity of adverse effects can be increased when Dyclonine is combined with Midazolam. Approved, Illicit Milnacipran The risk or severity of adverse effects can be increased when Dyclonine is combined with Milnacipran. Approved Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved, Investigational Mirtazapine Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Molindone The risk or severity of adverse effects can be increased when Dyclonine is combined with Molindone. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Dyclonine. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Dyclonine is combined with Nalbuphine. Approved Nefazodone The risk or severity of adverse effects can be increased when Dyclonine is combined with Nefazodone. Approved, Withdrawn Nitrazepam The risk or severity of adverse effects can be increased when Dyclonine is combined with Nitrazepam. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Dyclonine is combined with Nitrous oxide. Approved, Vet Approved Norflurane The risk or severity of adverse effects can be increased when Dyclonine is combined with 1,1,1,2 Tetrafluoroethane. Investigational Normethadone The risk or severity of adverse effects can be increased when Dyclonine is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Dyclonine is combined with Nortriptyline. Approved Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Dyclonine. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Dyclonine is combined with Olopatadine. Approved Ondansetron The risk or severity of adverse effects can be increased when Dyclonine is combined with Ondansetron. Approved Opium The risk or severity of adverse effects can be increased when Dyclonine is combined with Opium. Approved, Illicit Orphenadrine Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Dyclonine is combined with Osanetant. Investigational Oxazepam The risk or severity of adverse effects can be increased when Dyclonine is combined with Oxazepam. Approved Oxethazaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Oxetacaine. Investigational Oxprenolol The risk or severity of adverse effects can be increased when Dyclonine is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Oxybuprocaine. Approved Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Dyclonine. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Dyclonine is combined with Oxymorphone. Approved, Investigational, Vet Approved Paliperidone The risk or severity of adverse effects can be increased when Dyclonine is combined with Paliperidone. Approved Paraldehyde Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved Paroxetine The risk or severity of adverse effects can be increased when Dyclonine is combined with Paroxetine. Approved, Investigational Pentazocine The risk or severity of adverse effects can be increased when Dyclonine is combined with Pentazocine. Approved, Vet Approved Pentobarbital The risk or severity of adverse effects can be increased when Pentobarbital is combined with Dyclonine. Approved, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved Perazine The risk or severity of adverse effects can be increased when Dyclonine is combined with Perazine. Investigational Perospirone The risk or severity of adverse effects can be increased when Dyclonine is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Dyclonine is combined with Perphenazine. Approved Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Dyclonine. Approved Phenobarbital The risk or severity of adverse effects can be increased when Dyclonine is combined with Phenobarbital. Approved Phenoxyethanol The risk or severity of adverse effects can be increased when Dyclonine is combined with Phenoxyethanol. Approved Phenytoin The risk or severity of adverse effects can be increased when Dyclonine is combined with Phenytoin. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Dyclonine is combined with Pimozide. Approved Pipamperone The risk or severity of adverse effects can be increased when Dyclonine is combined with Pipamperone. Approved Pipotiazine The risk or severity of adverse effects can be increased when Dyclonine is combined with Pipotiazine. Approved Piritramide The risk or severity of adverse effects can be increased when Dyclonine is combined with Piritramide. Investigational Pizotifen The risk or severity of adverse effects can be increased when Dyclonine is combined with Pizotifen. Approved Pomalidomide The risk or severity of adverse effects can be increased when Dyclonine is combined with Pomalidomide. Approved Pramipexole Dyclonine may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Dyclonine is combined with Prazepam. Approved, Illicit Pregabalin The risk or severity of adverse effects can be increased when Pregabalin is combined with Dyclonine. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Prilocaine. Approved Primidone The risk or severity of adverse effects can be increased when Dyclonine is combined with Primidone. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Procaine. Approved, Investigational, Vet Approved Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dyclonine. Approved, Vet Approved Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Dyclonine. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Dyclonine is combined with Promethazine. Approved Proparacaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Proparacaine. Approved, Vet Approved Propofol The risk or severity of adverse effects can be increased when Dyclonine is combined with Propofol. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Propoxycaine. Approved Protriptyline The risk or severity of adverse effects can be increased when Dyclonine is combined with Protriptyline. Approved PSD502 The risk or severity of adverse effects can be increased when Dyclonine is combined with PSD502. Investigational Quazepam The risk or severity of adverse effects can be increased when Dyclonine is combined with Quazepam. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Dyclonine is combined with Quetiapine. Approved Raclopride The risk or severity of adverse effects can be increased when Dyclonine is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Dyclonine is combined with Ramelteon. Approved, Investigational Remifentanil The risk or severity of adverse effects can be increased when Dyclonine is combined with Remifentanil. Approved Remoxipride The risk or severity of adverse effects can be increased when Remoxipride is combined with Dyclonine. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Dyclonine. Approved Risperidone The risk or severity of adverse effects can be increased when Dyclonine is combined with Risperidone. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Dyclonine is combined with Ritanserin. Investigational Romifidine The risk or severity of adverse effects can be increased when Dyclonine is combined with Romifidine. Vet Approved Ropinirole Dyclonine may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dyclonine. Approved Rotigotine Dyclonine may increase the sedative activities of Rotigotine. Approved Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Dyclonine. Approved Scopolamine The risk or severity of adverse effects can be increased when Dyclonine is combined with Scopolamine. Approved Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Dyclonine. Approved, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Dyclonine is combined with Uc1010. Investigational Sertindole The risk or severity of adverse effects can be increased when Dyclonine is combined with Sertindole. Approved, Withdrawn Sertraline The risk or severity of adverse effects can be increased when Dyclonine is combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Dyclonine is combined with Sevoflurane. Approved, Vet Approved Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved Stiripentol The risk or severity of adverse effects can be increased when Dyclonine is combined with Stiripentol. Approved Sufentanil The risk or severity of adverse effects can be increased when Dyclonine is combined with Sufentanil. Approved, Investigational Sulpiride The risk or severity of adverse effects can be increased when Sulpiride is combined with Dyclonine. Approved Suvorexant Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved Tandospirone The risk or severity of adverse effects can be increased when Dyclonine is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine. Approved Tasimelteon The risk or severity of adverse effects can be increased when Dyclonine is combined with Tasimelteon. Approved Technetium Tc-99m tilmanocept Dyclonine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent. Approved Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Dyclonine. Approved Tetrabenazine The risk or severity of adverse effects can be increased when Dyclonine is combined with Tetrabenazine. Approved Tetracaine The risk or severity of adverse effects can be increased when Dyclonine is combined with Tetracaine. Approved, Vet Approved Tetrodotoxin The risk or severity of adverse effects can be increased when Dyclonine is combined with Tetrodotoxin. Investigational Thalidomide Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Thiamylal The risk or severity of adverse effects can be increased when Dyclonine is combined with Thiamylal. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Thiopental is combined with Dyclonine. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Dyclonine is combined with Thioridazine. Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Dyclonine is combined with Thiothixene. Approved Tiagabine The risk or severity of adverse effects can be increased when Dyclonine is combined with Tiagabine. Approved Tiapride The risk or severity of adverse effects can be increased when Dyclonine is combined with Tiapride. Approved, Investigational Tiletamine The risk or severity of adverse effects can be increased when Dyclonine is combined with Tiletamine. Vet Approved Tizanidine The risk or severity of adverse effects can be increased when Dyclonine is combined with Tizanidine. Approved Tolcapone The risk or severity of adverse effects can be increased when Dyclonine is combined with Tolcapone. Approved, Withdrawn Topiramate The risk or severity of adverse effects can be increased when Dyclonine is combined with Topiramate. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Dyclonine. Approved, Investigational Trans-2-Phenylcyclopropylamine The risk or severity of adverse effects can be increased when Dyclonine is combined with Trans-2-Phenylcyclopropylamine. Experimental Tranylcypromine The risk or severity of adverse effects can be increased when Dyclonine is combined with Tranylcypromine. Approved Trazodone The risk or severity of adverse effects can be increased when Dyclonine is combined with Trazodone. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Dyclonine is combined with Triazolam. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Dyclonine is combined with Trifluoperazine. Approved Triflupromazine The risk or severity of adverse effects can be increased when Triflupromazine is combined with Dyclonine. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Dyclonine is combined with Trimipramine. Approved Triprolidine The risk or severity of adverse effects can be increased when Dyclonine is combined with Triprolidine. Approved Valproic Acid The risk or severity of adverse effects can be increased when Valproic Acid is combined with Dyclonine. Approved, Investigational Venlafaxine The risk or severity of adverse effects can be increased when Dyclonine is combined with Venlafaxine. Approved Vigabatrin The risk or severity of adverse effects can be increased when Dyclonine is combined with Vigabatrin. Approved Vortioxetine The risk or severity of adverse effects can be increased when Dyclonine is combined with Vortioxetine. Approved Xylazine The risk or severity of adverse effects can be increased when Dyclonine is combined with Xylazine. Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Dyclonine is combined with Zaleplon. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Dyclonine is combined with Ziconotide. Approved Zimelidine The risk or severity of adverse effects can be increased when Dyclonine is combined with Zimelidine. Withdrawn Ziprasidone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Dyclonine. Approved Zolazepam The risk or severity of adverse effects can be increased when Dyclonine is combined with Zolazepam. Vet Approved Zolpidem Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Dyclonine is combined with Zonisamide. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Dyclonine is combined with Zopiclone. Approved Zotepine The risk or severity of adverse effects can be increased when Dyclonine is combined with Zotepine. Approved Zuclopenthixol The risk or severity of adverse effects can be increased when Dyclonine is combined with Zuclopenthixol. Approved, Investigational - Food Interactions
- Not Available
References
- Synthesis Reference
Tianjiang Sun, Xiaohong Gu, Hongguo Lu, Min Chen, "Oral Preparation of Dyclonine Hydrochloride." U.S. Patent US20080200506, issued August 21, 2008.
US20080200506- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB14783
- KEGG Compound
- C07881
- PubChem Compound
- 3180
- PubChem Substance
- 46506697
- ChemSpider
- 3068
- ChEBI
- 4724
- ChEMBL
- CHEMBL1201217
- Therapeutic Targets Database
- DAP000509
- PharmGKB
- PA164748037
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Dyclonine
- ATC Codes
- N01BX02 — DyclonineR02AD04 — Dyclonine
- AHFS Codes
- 52:16.00
- PDB Entries
- Not Available
- FDA label
- Not Available
- MSDS
- Download (73.4 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1, 2 Completed Treatment Gingival Inflammation 1
Pharmacoeconomics
- Manufacturers
- Astrazeneca lp
- Packagers
- Dosage forms
Form Route Strength Cream Topical Liquid Topical Liquid Oral Spray Oral 0.1 % Rinse Dental; Oral; Topical; Transmucosal .1 g/100mL Lozenge Oral 3 mg/1 Lozenge Oral 1.2 mg/1 Lozenge Oral Lozenge Oral 1.2 mg Lozenge Oral 2 mg Lozenge Oral 3 mg Aerosol Oral .1 % Lozenge Oral 2 mg/1 Gel Topical - Prices
Unit description Cost Unit Dyclonine hcl powder 4.9USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 174-175 Bockstahler, E.R.; U.S.Patent 2,771,391; November 20,1956; assigned to Allied Laboratories, Inc. Florestano, H.J., Jeffries, S.F., Osborne, C.E. and Bahler, M.E.; U.S. Patent 2,868,689; January 13, 1959; assigned to Allied Laboratories, Inc. water solubility Soluble (HCl salt) Not Available logP 3.7 Not Available - Predicted Properties
Property Value Source Water Solubility 0.046 mg/mL ALOGPS logP 4.11 ALOGPS logP 3.68 ChemAxon logS -3.8 ALOGPS pKa (Strongest Acidic) 15.88 ChemAxon pKa (Strongest Basic) 8.36 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 29.54 Å2 ChemAxon Rotatable Bond Count 8 ChemAxon Refractivity 87.07 m3·mol-1 ChemAxon Polarizability 35.14 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9856 Caco-2 permeable + 0.7155 P-glycoprotein substrate Substrate 0.7596 P-glycoprotein inhibitor I Inhibitor 0.8077 P-glycoprotein inhibitor II Non-inhibitor 0.6392 Renal organic cation transporter Inhibitor 0.7801 CYP450 2C9 substrate Non-substrate 0.8107 CYP450 2D6 substrate Non-substrate 0.5142 CYP450 3A4 substrate Substrate 0.5313 CYP450 1A2 substrate Inhibitor 0.8914 CYP450 2C9 inhibitor Inhibitor 0.793 CYP450 2D6 inhibitor Inhibitor 0.8932 CYP450 2C19 inhibitor Non-inhibitor 0.9026 CYP450 3A4 inhibitor Non-inhibitor 0.8574 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.5388 Ames test Non AMES toxic 0.7961 Carcinogenicity Non-carcinogens 0.8823 Biodegradation Not ready biodegradable 0.7106 Rat acute toxicity 2.3661 LD50, mol/kg Not applicable hERG inhibition (predictor I) Strong inhibitor 0.8071 hERG inhibition (predictor II) Inhibitor 0.6351
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted LC-MS/MS Spectrum - 10V, Positive Predicted LC-MS/MS Not Available Predicted LC-MS/MS Spectrum - 20V, Positive Predicted LC-MS/MS Not Available Predicted LC-MS/MS Spectrum - 40V, Positive Predicted LC-MS/MS Not Available Predicted LC-MS/MS Spectrum - 10V, Negative Predicted LC-MS/MS Not Available Predicted LC-MS/MS Spectrum - 20V, Negative Predicted LC-MS/MS Not Available Predicted LC-MS/MS Spectrum - 40V, Negative Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of chemical entities known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
- Kingdom
- Chemical entities
- Super Class
- Organic compounds
- Class
- Organic oxygen compounds
- Sub Class
- Organooxygen compounds
- Direct Parent
- Alkyl-phenylketones
- Alternative Parents
- Phenoxy compounds / Phenol ethers / Benzoyl derivatives / Aryl alkyl ketones / Alkyl aryl ethers / Piperidines / Beta-amino ketones / Trialkylamines / Azacyclic compounds / Organopnictogen compounds show 2 more
- Substituents
- Alkyl-phenylketone / Phenoxy compound / Benzoyl / Phenol ether / Aryl alkyl ketone / Alkyl aryl ether / Monocyclic benzene moiety / Beta-aminoketone / Piperidine / Benzenoid show 12 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- piperidines, aromatic ketone (CHEBI:4724 )
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated sodium channel activity
- Specific Function
- Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference acro...
- Gene Name
- SCN10A
- Uniprot ID
- Q9Y5Y9
- Uniprot Name
- Sodium channel protein type 10 subunit alpha
- Molecular Weight
- 220623.605 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
- Roghani S, Duperon DF, Barcohana N: Evaluating the efficacy of commonly used topical anesthetics. Pediatr Dent. 1999 May-Jun;21(3):197-200. [PubMed:10355012 ]
- Tella SR, Goldberg SR: Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. [PubMed:9476974 ]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:30